Expert Insights

Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...

Claire Harrison, MD, discusses results from the phase 3 SENTRY trial showing that selinexor plus ruxolitinib significantly improved spleen responses and overall survival while demonstrating evidence of disease modification in patients with...

Claire Harrison, MD, discusses updated phase 1 data showing that the mutant CALR-targeted monoclonal antibody INCA033989 produced meaningful clinical and molecular responses with a favorable safety profile in patients with CALR-mutant...

Bjørn Henning Grønberg, MD, PhD, professor and consultant in oncology at the Norwegian University of Science and Technology and St. Olavs Hospital in Trondheim, Norway, discusses results from a phase 3 randomized trial evaluating the addition...

Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...

Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...

Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...

Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.

Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...

Kevin Kalinsky, MD, discusses updated results from the ASCENT-04 trial showing that sacituzumab govitecan plus pembrolizumab continued to provide durable clinical benefit beyond initial progression, supporting its use as a frontline treatment...